Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,037 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dietary sodium Clear all
Completed Phase 2 Interventional Results available

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

NCT03784079
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Placebo matching GSK3640254 Mesylate salt
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Bakersfield, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT00957905
View directory record Official record
Conditions
Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor, Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage III Testicular Cancer, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions
Alvocidib Hydrochloride, Fluorouracil, Leucovorin Calcium, Oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 16, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Phosphorus Additives on the Metabolome in Healthy Adults

NCT03841786
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Sensitivity, Cardiovascular Diseases
Interventions
Phosphorus-supplemented study diet, Control Diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism of Ornithine Phenylacetate

NCT03159390
View directory record Official record
Conditions
Healthy
Interventions
phenylacetate salt of ornithine
Other
Lead sponsor
Texas A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Study of Minnelide™ in Patients With Advanced GI Tumors

NCT01927965
View directory record Official record
Conditions
Advanced Gastrointestinal Tumors
Interventions
Minnelide™ 001
Drug
Lead sponsor
Minneamrita Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rehydration Following Exercise-Induced Dehydration

NCT01974986
View directory record Official record
Conditions
Dehydration Related to Exercise
Interventions
Water with flavoring and non-nutritive sweetener., High-Na low-CHO beverage, Low-Na high-CHO beverage
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 1Phase 2 Interventional

The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke

NCT01088230
View directory record Official record
Conditions
Stroke
Interventions
Botox®, saline solution
Other
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 16, 2026, 8:59 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

NCT07772492
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Meridian, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 16, 2026, 8:59 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Gut Microbiome, Metabolome, and SSBP

NCT07790900
View directory record Official record
Conditions
Salt-sensitivity of Blood Pressure
Interventions
Dietary sodium
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

NCT02059031
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 Reference formulation, GSK1265744 New formulation 1, GSK1265744 New formulation 2
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 16, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

NCT00945477
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
Illinois CancerCare, P.C.
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Bloomington, Illinois • Ottawa, Illinois • Pekin, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 16, 2026, 8:59 AM EDT
Withdrawn Phase 1 Interventional

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

NCT02856568
View directory record Official record
Conditions
Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Extrahepatic Bile Duct Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IVA Extrahepatic Bile Duct Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Extrahepatic Bile Duct Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ricolinostat
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Studies on Aldosterone and Vascular Function

NCT00700479
View directory record Official record
Conditions
Inflammation
Interventions
aldosterone, low or high sodium diet, placebo
Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Dietary Sodium Supplementation on Growth & Intestinal Microbiome

NCT05546814
View directory record Official record
Conditions
Preterm Birth
Interventions
Sodium algorithm
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
25 Weeks to 30 Weeks
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 16, 2026, 8:59 AM EDT
Active, not recruiting Not applicable Interventional

Renal Metabolism in Salt-sensitive Human Blood Pressure

NCT05369416
View directory record Official record
Conditions
Hypertension
Interventions
Low sodium diet, high sodium diet
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
30 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 16, 2026, 8:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Salt and TH-17 in Healthy Human Subjects

NCT02261688
View directory record Official record
Conditions
Th17 Helper Immune Cells, Autoimmunity, Salt Intake, Sodium Chloride
Interventions
Low salt diet, Low salt diet + IV normal saline, Liberal salt diet
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

NCT01824082
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Perineural infusion [continuous peripheral nerve block(s)]
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

NCT03384966
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Selatogrel, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

NCT01888302
View directory record Official record
Conditions
Hepatic Complication
Interventions
Cisplatin, Gemcitabine Hydrochloride, Quality-of-Life Assessment, Sirolimus
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 16, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

NCT03170375
View directory record Official record
Conditions
Heart Failure
Interventions
Performance of WHEELS-I in promoting DASH/SRD adoption
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 16, 2026, 8:59 AM EDT